Keros Q1 net loss $35.8M, cash $351.4M; KER-012 Phase 2 starts H1 2023

Keros Therapeutics, Inc.

2023-Q1 EPS reported -$1.26

Net loss of $35.8M vs $24.2M in Q1 2022; R&D spend $31.1M (+$13.0M YoY) driving pipeline.
Cash and equivalents $351.4M as of March 31, 2023; runway into Q4 2025.
Dr. Alpna Seth appointed to board of directors in May 2023.
KER-012 Phase 2 trial for pulmonary arterial hypertension planned to start H1 2023.
KER-050 Phase 2 data readouts in MDS and myelofibrosis expected later this year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Keros Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income net loss of $35.8 million.

Period: the quarter ended March 31, 2023
Net income: net loss of $35.8 million
Result: reported results

Exact text from the filing

Keros reported a net loss of $35.8 million in the first quarter of 2023 as compared to a net loss of $24.2 million in the first quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-23-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.